Last checked at 19 Apr 2023 18:26
2022 preliminary results revised date, guidance unchanged
Oxford, UK - 19 April 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led viral vector CDMO, today announces a revised date for the publication of its preliminary results for the year ended 31 December 2022.
The Company's auditor, KPMG LLP, has requested additional time to complete its standard procedures due to the increased scope of the expanded business.
As a result, the Company will now announce its results on Tuesday 25 April 2023, a delay to the previously planned date of 20 April 2023.
Oxford Biomedica reiterates guidance given at the time of its interim results and confirms that the change of results date has not arisen as a result of any concerns relating to the 2022 financial results or the future outlook of the Company.
-Ends-
Enquiries:
Oxford Biomedica plc:
Taylor Boyd, VP, Head of IR - T: +1 919 539 1234 / E: ir@oxb.com
Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0) 7394 562 425 / E: ir@oxb.com
Consilium Strategic Communications:
T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com
Mary-Jane Elliott / Matthew Neal / Davide Salvi
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in gene and cell therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and a US-based subsidiary, Oxford Biomedica Solutions, based near Boston, US. Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on LinkedIn, Twitter and YouTube.